9:47 AM
 | 
Oct 26, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. Merck & Co. Inc. (NYSE:MRK) and Eli Lilly and Co. (NYSE:LLY) each presented data at the European Society for Medical Oncology meeting in Munich showing that MK-1454 and pegilodecakin (AM0010) led to no responses as monotherapies across several indications, despite showing some efficacy in combination with chemotherapy or checkpoint inhibitors.

Merck reported that MK-1454 as monotherapy led to no responses in 20 evaluable patients in a Phase I trial to treat advanced solid tumors or lymphomas. The disease control rate in the monotherapy arm for the transmembrane protein 173...

Read the full 592 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >